Investing in PainChek Limited, traded on the ASX under the ticker PCK, carries typical small-cap biotechnology and healthcare technology risks, including ongoing operational net losses, capital-raising dilution requirements, and execution hurdles associated with commercializing software globally. Additionally, widespread adoption relies heavily on complex regulatory approvals, healthcare institutional procurement cycles, and navigating competitive digital health landscapes across international aged care and clinical markets.